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Vascular Changes: A New Player in
the Arena?
Salah D. Qanadli*, Ana Carolina Rocha and David C. Rotzinger*
Cardiothoracic and Vascular Division, Department of Diagnostic and Interventional Radiology, Lausanne University Hospital
and University of Lausanne, Lausanne, Switzerland
Up to now, COVID-19-related vascular changes were mainly described as thrombo-
embolic events. A handful of researchers reported another type of vascular abnormality
referred to as “vascular thickening” or “vascular enlargement,” without specifying whether
the dilated vessels are arteries or veins nor providing a physiopathological hypothesis.
Our observations indicate that the vascular dilatation occurs in the venous compartment,
and underlying mechanisms might include increased blood flow due to inflammation and
the activation of arteriovenous anastomoses.
Keywords: COVID-19, computed tomography, perfusion, pulmonary embolism, arteriovenous anastomoses,
respiratory failure
INTRODUCTION
Early in the coronavirus disease 2019 (COVID-19) pandemic, a high prevalence of vascular
disorders has been reported (1). Such abnormalities were mainly described in the lung and covered
a broad spectrum of patterns revealed at histology–including microangiopathy, intussusceptive
angiogenesis, and microthrombosis–and at imaging with vessel dilatation, tortuosity, thrombosis,
and perfusion abnormalities. Up to now, no convincing theory has helped understand the
relationship between virus-induced inflammatory disorders and biological and morphological
changes, especially those observed on computed tomography (CT). Furthermore, the refractory
hypoxemia observed in COVID-19 patients appears to be driven by more complex processes than
alveolar damage with low gas exchange alone because COVID-19 leads to severe respiratory failure
despite relatively well-preserved lung gas volume (2). This suggests the contribution of vascular
phenomena beyond a simple ventilation–perfusion mismatch.
VASCULAR CHANGES IN COVID-19 PNEUMONIA
Imaging-based morphological vascular abnormalities in the lung described at CT may be
categorized into three groups: thromboembolic events (3), vascular dilatation, also known as
vascular “thickening” or “engorgement” (4, 5), and perfusional changes (6). Mechanisms leading
to vascular remodeling remain unclear, and their prevalence and distribution are a matter of
debate. We analyzed CT data from a patient who presented all the three groups of abnormalities
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FIGURE 1 | Contrast-enhanced chest CT in a patient admitted for COVID-19.
Coronal reformatted image (a) shows peripheral ground-glass opacity (GGO)
predominantly involving the right lower lobe. Tissue classification (b)
distinguishing alveolar opacity (peach color code) from normal parenchyma
(blue) and vascular components (red) visually indicates vascular enlargement in
COVID-19 pneumonia. Specific thresholds to isolate voxels, mostly containing
vascular elements (c,d), enable vascular volume extraction in
regions-of-interest. Center-line reconstructions of the right posterior basal
artery and vein (e,f) allow diameter measurement in GGO. Axial conventional
image in lung window (g) with peripheral COVID-19-related GGO and
corresponding dual-energy CT iodine density map (h) show increased iodine
distribution in GGO consistent with hyperperfusion.
simultaneously and thoroughly assessed vascular findings, trying
to understand the different groups’ relationships and elucidate
the underlying mechanisms.
A man in his 70’s with fever, tachypnea, bilateral basal
crackling sounds, and reverse transcription-PCR (RT-PCR)-
proven severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection underwent dual-energy CT pulmonary
angiography to rule out pulmonary embolism. Arterial PaO2 was
64 mmHg, and SpO2 was 92% on room air. The examination
was carried out on a fast kV-switching dual-energy CT platform
(Revolution CT, GE Healthcare), with the following parameters:
rotation speed, 0.5 s; tube load, 180 mAs; reconstructed slice
thickness, 1.25mm; and section interval, 1mm. Using a power
injector, 50ml of iodinated contrast material (Accupaque 300 R©)
was injected through an 18G venous catheter in the right
antecubital fossa at a rate of 4 ml/s and followed by a saline
chaser. Findings included zones of COVID-19 ground-glass
opacity (GGO) surrounded by healthy parenchyma, enlarged
blood vessels within GGO, and acute pulmonary embolism in
a lung segment without GGO. We applied automatic tissue
classification to distinguish alveolar opacity, normal parenchyma,
and vascular components (Figures 1a,b). In a second step, we
used a threshold-based automatic segmentation to extract the
(macroscopic) intravascular blood volume in a region-of-interest
(ROI) in both normal parenchyma and GGO (Figures 1c,d).
Calculated intravascular blood volumes showed that in the
areas presenting with typical parenchymal changes, the vascular
volume was increased by 40% (5.27/300 and 9.0/300 cm3
vessel-to-tissue ratio in healthy and GGO zones, respectively).
Of note, no venous thrombosis was seen. Furthermore, we
demonstrate that the increased volume primarily depended on
venous dilatation in the involved lung areas (Figures 1e,f).
Arterial and venous diameters at a sub-segmental level in
GGO were 3.6 and 4.9mm, respectively, whereas in the healthy
contralateral posterior basal segment, diameters were 3.0 and
3.1mm, respectively. The corresponding artery-to-vein ratios are
0.97 (3.0/3.1) in healthy parenchyma and 0.73 (3.6/4.9) in GGO,
and the vein-to-vein ratio (GGO vs. healthy segment) was 1.58
(4.9/3.1), indicating marked venous enlargement in COVID-
19-related GGO. Note that the artery-to-artery ratio (GGO vs.
healthy segment) was 1.2 (3.6/3), indicating a moderate arterial
dilatation in GGO consistent with hyperemia.
DISCUSSION
Inflammation-mediated hyperemia is unlikely to be the only
factor causing such amarked venous dilatation.We hypothesized
that the upregulation of nitric oxide synthase, causing the
activation of physiological arteriovenous anastomoses (7, 8) in
the involved parenchyma, might explain venous engorgement;
these anastomoses create a right-to-left shunt. The existence
of pulmonary arteriovenous anastomoses has been suggested
and studied by Tobin et al. since the 1950’s, and their
anatomical location was described as “at the apex of and
within the lobular divisions of the lung” (9, 10). Available
data suggest that such anastomoses can be activated passively
by exercise or supine position, but also actively in the setting
of vascular redistribution under both hyperoxia and hypoxia
(11). In COVID-19 pneumonia, the consequence of combined
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mechanisms is exacerbated hypoxia, giving a better explanation
for the discrepancies between the relatively preserved ventilation
mechanics, the severity of respiratory failure, and the limited
response to invasive ventilation (2). Other injuries, such as
endotheliitis (12) and/or distal microthrombosis (13), might
potentialize the dysregulation of intrapulmonary arteriovenous
anastomoses and the resulting shunting effect. In the case we
discuss here, transthoracic saline echocardiography would have
been a simple and effective means of evaluating the presence of
intrapulmonary anastomoses and should have been performed
if possible (14). Furthermore, recent evidence suggests that the
recruitment of intrapulmonary arteriovenous anastomoses may
be driven by the combination of increased cardiac output and
increased pulmonary vascular pressure (8). Unfortunately, we
could not provide a meaningful estimation of cardiac output
based on the available data.
The observed phenomenon is consistent with previously
described increased parenchymal perfusion in COVID-
19 GGO with dual-energy CT (6). Likewise, our patient
exhibited hyperperfusion in GGO zones on iodine density
maps (Figures 1g,h). This distal hyperperfusion is attributed
to hyperemia induced by the inflammation cascade in
COVID-19 pneumonia.
It is also interesting to note that macro-thromboembolic
changes (pulmonary embolism) were observed in a different
territory than those with parenchymal involvement. This might
be another consequence of the vascular shunting effect. This
finding is also in agreement with a previous report (15).
In conclusion, our observations indicate that COVID-19-
related macroscopic vascular changes depicted in vivo are not
exclusively due to thromboembolic events. The observed vascular
remodeling is mainly related to venous dilatation and might
result from combined inflammation-induced hyperemia and
dysregulation of arteriovenous anastomoses. Although difficult
to establish in vivo, vascular shunts could explain the worse than
expected clinical course given a relatively modest parenchymal
involvement and no visible local thromboembolism. Further
studies aiming to characterize those abnormalities in a large
series, particularly their distribution and correlation to clinical
findings, are needed. The core message of this letter is to frame
the hypothesis of intrapulmonary arteriovenous anastomoses as
an influencing factor in patients with COVID-19 pneumonia,
and the images presented in this case study serve for illustration
purposes. An ongoing investigation, the Swiss National Registry
COVID-CAVA, is expected to provide relevant insights to
address those crucial questions better.
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